Holen Sie sich die Stockscreener-App
155.73
0.62%
-0.97
Handel nachbörslich:
156.00
0.27
+0.17%
Schlusskurs vom Vortag:
$156.70
Offen:
$158
24-Stunden-Volumen:
975.13K
Relative Volume:
0.86
Marktkapitalisierung:
$15.66B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$668.60M
KGV:
23.94
EPS:
6.5044
Netto-Cashflow:
$831.30M
1W Leistung:
+0.89%
1M Leistung:
+21.97%
6M Leistung:
+2.74%
1J Leistung:
+29.58%
1-Tages-Spanne:
$155.66
$158.25
1-Wochen-Bereich:
$152.54
$158.63
52-Wochen-Spanne:
$119.62
$162.39
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
155.73 | 15.76B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
NBIX (NASDAQ: NBIX) broker files Form 144 to sell 3,888 shares - Stock Titan
Neurocrine to stream June investor fireside chats from Chicago, Miami - Stock Titan
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform - Insider Monkey
(NBIX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Neurocrine Biosciences, Inc. (NBIX): Investor Outlook Reveals 22.56% Potential Upside - DirectorsTalk Interviews
Singer Carnie Wilson Finds Strength in Speaking Out on Mental Health Challenges - SELF Magazine
Bernstein Initiates Coverage on Neurocrine Biosciences With Outperform Rating - Moomoo
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential - ChartMill
Bernstein initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock By Investing.com - Investing.com South Africa
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock - Investing.com UK
Director Shalini Sharp converts 1,659 RSUs into NBIX common stock shares - Stock Titan
NBIX (NBIX) director converts 3,318 RSUs into 10,386 common shares - Stock Titan
Neurocrine (NASDAQ: NBIX) director converts 3,318 RSUs to shares - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) converts 3,318 RSUs to stock - Stock Titan
Neurocrine Biosciences (NBIX) director converts 3,318 RSUs into 3,318 shares - Stock Titan
Neurocrine (NBIX) director converts 3,318 RSUs into common shares - Stock Titan
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Johanna Mercier (NBIX) converts 3,318 RSUs into Neurocrine Biosciences stock - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) converts 1,659 RSUs to shares - Stock Titan
Bernstein initiates Neurocrine stock with outperform rating on drug potential - Investing.com
Bernstein initiates Neurocrine stock with outperform rating on drug potential By Investing.com - Investing.com Canada
Neurocrine Biosciences stock (US62886E1082): focus on INGREZZA momentum and growth outlook - AD HOC NEWS
Will New Real-World INGREZZA (valbenazine) Data in Mild TD Change Neurocrine Biosciences' (NBIX) Narrative - Yahoo Finance
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention - Yahoo Finance
Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention - simplywall.st
New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st
Morgan Stanley lists Rule 144 sale of NBIX shares (NBIX) - Stock Titan
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
New data support early use of Ingrezza in mild tardive dyskinesia - The Pharma Letter
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal - RTTNews
Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules - Moomoo
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock By Investing.com - Investing.com Australia
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com UK
Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK
Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Neurocrine (NBIX) Reveals Positive Data on INGREZZA for Mild Tar - GuruFocus
Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia
Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com South Africa
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sharp Shalini | Director |
May 21 '26 |
Option Exercise |
0.00 |
1,659 |
0 |
4,088 |
| RASTETTER WILLIAM H | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
43,678 |
| POPS RICHARD F | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
37,798 |
| POON CHRISTINE A | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
4,753 |
| Norwalk Leslie V | Director |
May 21 '26 |
Option Exercise |
0.00 |
1,659 |
0 |
4,088 |
| MORROW GEORGE J | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
10,386 |
| Mercier Johanna | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
6,853 |
| LYONS GARY A | Director |
May 21 '26 |
Option Exercise |
0.00 |
1,659 |
0 |
122,141 |
| GORMAN KEVIN CHARLES | Director |
May 19 '26 |
Option Exercise |
43.24 |
205,088 |
8,868,005 |
756,381 |
| GORMAN KEVIN CHARLES | Director |
May 19 '26 |
Sale |
154.33 |
245,088 |
37,824,872 |
511,293 |
2.34%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):